Dr. Stephen D. Collins MD, PhD

Stephen D. Collins, MD, PhD’s career has focused on the research and clinical development of therapeutics for a broad range of disorders. Currently he serves on the boards of several biotechnology companies. In addition to his Chairmanship of Xalud Therapeutics he serves as President and CEO of Biscayne Pharmaceuticals a company specializing in the development of treatmeants for severe, life-threatening neurologic diseases.

Previously Dr. Collins was the President and CEO of NeuroTherapeutics Pharma, an early stage biotechnology company. Prior to NeuroTherapeutics Pharma, he was Chief Scientific Officer & VP for Clinical Affairs of Ovation Pharmaceuticals. Dr. Collins was a Global Director at Johnson & Johnson, overseeing the early-stage development of a variety of agents. He was also a member of the global in-licensing advisory team. Prior to Johnson and Johnson, he worked in Abbott Laboratories’ Pharmaceutical and Hospital Products Divisions.

Previous to his industry experience, Dr. Collins was on the faculty of medicine at both Case Western Reserve University and the University of California-San Francisco. Dr. Collins earned his MD and PhD at Case Western Reserve University and performed his undergraduate studies in Physics at the University of California, Berkeley.